Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005

Diabetologia

Volumn 49, Issue 1, 2006, Pages 11-19

  Rossing, P ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

ACE inhibition; Diabetic nephropathy; Dual blockade; Epidemiology; Microalbuminuria; Progression of renal disease; Progression promoters; Type 1 diabetes

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CANDESARTAN; CAPTOPRIL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH FACTOR; IRBESARTAN; LISINOPRIL; LOSARTAN; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE; TRANDOLAPRIL;

BLOOD CLOTTING; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; GENETIC MARKER; GENETIC RISK; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODYNAMICS; HIGH RISK POPULATION; HORMONE INHIBITION; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; LOW BIRTH WEIGHT; MICROALBUMINURIA; NONHUMAN; ORAL CONTRACEPTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; THERAPY EFFECT;

BIOLOGICAL MARKERS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 31444451184     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-0077-3     Document Type: Review

References (115)

1. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T (1983) Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25:496-501
2. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR (1985) The changing natural history of nephropathy in Type 1 diabetes. Am J Med 78:785-794
3. Ballard DJ, Humphrey LL, Melton LJ 3rd et al (1988) Epidemiology of persistent proteinuria in Type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 37:405-412
4. Rossing P (2005) The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 48:1439-1444
5. Mogensen CE, Keane WF, Bennett PH et al (1995) Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080-1084
6. Rossing P, Hougaard P, Parving HH (2002) Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 25: 859-864
7. Hovind P, Tarnow L, Rossing P et al (2004) Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. Br Med J 328:1105
8. Seaquist ER, Goetz FC, Rich S, Barbosa J (1989) Familial clustering of diabetic kidney disease: Evidence of genetic susceptibility to diabetic nephropathy. N Engl J Med 320:1161-1165
9. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC (1990) Familial predisposition to renal disease in two generations of Pima Indians with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33:438-443
10. Borch-Johnsen K, Nørgaard K, Hommel E et al (1992) Is diabetic nephropathy an inherited complication? Kidney Int 41:719-722
11. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM (1989) Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 321:1074-1079
12. Tarnow L (2002) Diabetic nephropathy. Pathogenetic aspects and cardiovascular risk factors. Dan Med Bull 49:19-42
13. Tamow L, Gluud C, Parving HH (1998) Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 13:1125-1130
14. Brenner BM, Chertow GM (1994) Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Diseases 23:171-175
15. Rossing P, Tarnow L, Nielsen FS, Boelskifte S, Brenner BM, Parving HH (1995) Short stature and diabetic nephropathy. Br Med J 310:296-297
16. Gould MM, Mohamed-Ali V, Goubet SA, Yudkin JS, Haines AP (1993) Microalbuminuria: associations with height and sex in non-diabetic subjects. Br Med J 306:240-242
17. Rossing P, Tarnow L, Nielsen FS, Hansen BV, Brenner BM, Parving HH (1995) Low birth weight. A risk factor for development of diabetic nephropathy? Diabetes 44: 1405-1407
18. Luyckx VA, Brenner BM (2005) Low birth weight, nephron number, and kidney disease. Kidney Int Suppl S68-S77
19. Mathiesen ER, Rønn B, Jensen T, Storm B, Deckert T (1990) Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes 39:245-249
20. Coonrod BA, Ellis D, Becker DJ et al (1993) Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 16:1376-1383
21. Microalbuminuria Collaborative Study Group UK (1999) Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven year prospective study. Diabetic Med 16:918-925
22. Chaturvedi N, Bandinelli S, Mangili R et al (2001) Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 60:219-227
23. Lurbe E, Redon J, Kesani A et al (2002) Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 347:797-805
24. Daneman D, Crompton CH, Balfe JA et al (1994) Plasma prorenin as an early marker of nephropathy in diabetic (IDDM) adolescents. Kidney Int 46:1154-1159
25. Deinum J, Rønn B, Mathiesen ER, Derkx FHM, Hop WCJ, Schalekamp MADH (1999) Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 42:1006-1010
26. Ahmed SB, Hovind P, Parving HH et al (2005) Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 28:1988-1994
27. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT (2001) Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 161:2000-2005
28. Pirart J (1978) Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1:168-188
29. Rossing P, Hougaard P, Parving HH (2002) Risk factors for development of incipient and overt diabetic nephropathy in Type 1 diabetic patients. Diabetes Care 25:859-864
30. Scott LJ, Warram JH, Hanna LS, Laffel LM, Ryan L, Krolewski AS (2001) A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 50:2842-2849
31. Wang PH, Lau J, Chalmers TC (1993) Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 341:1306-1309
32. The Diabetes Control and Complications Trial Research Group. (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
33. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820
34. Du XL, Edelstein D, Rossetti L et al (2000) Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97:12222-12226
35. Nishikawa T, Edelstein D, Du XL et al (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790
36. Chase HP, Garg SK, Marshall G et al (1991) Cigarette smoking increases the risk of albuminuria among subjects with type 1 diabetes. JAMA 265:614-617
37. Mathiesen ER, Rønn B, Foght H, Deckert T (1995) The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. Diabetic Med 12:482-487
38. Hansen HP, Rossing P, Jacobsen P, Jensen BR, Parving HH (1996) The acute effect of smoking on systemic haemodynamics, kidney and endothelial function in insulin-dependent diabetic patients with microalbuminuria. Scand J Clin Lab Invest 56:393-399
39. Sawicki PT, Didjurgeit U, Mühlhauser I, Bender R, Heinemann L, Berger M (1994) Smoking is associated with progression of diabetic nephropathy. Diabetes Care 17:126-131
40. Hovind P, Rossing P, Tarnow L, Parving HH (2003) Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 26:911-916
41. Parving HH, Oxenbøll B, Svendsen PA, Christiansen JS, Andersen AR (1982) Early detection of patients at risk of developing diabetic nephropathy. Acta Endocrinol (Copenh) 100:550-555
42. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H (1982) Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet i:1430-1432
43. Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89-93
44. Rossing P, Hougaard P, Parving HH (2005) Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. Kidney Int 68:1446-1450
45. Chaturvedi N (2001) Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 134:370-379
46. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS (2003) Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348:2285-2293
47. Caramori ML, Fioretto P, Mauer M (2000) The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 49:1399-1408
48. Forsblom CM, Groop P-H, Ekstrand A, Groop L (1992) Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration. Br Med J 305:1051-1053
49. Arun CS, Stoddart J, Mackin P, MacLeod JM, New JP, Marshall SM (2003) Significance of microalbuminuria in long-duration type 1 diabetes. Diabetes Care 26:2144-2149
50. Giorgino F, Laviola L, Cavallo PP, Solnica B, Fuller J, Chaturvedi N (2004) Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 47:1020-1028
51. Warram JH, Scott LJ, Hanna LS et al (2000) Progression of microalbuminuria to proteinuria in type 1 diabetes: nonlinear relationship with hyperglycemia. Diabetes 49:94-100
52. Microalbuminuria Collaborative Study Group, UK (1995) Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 311:973-977
53. Hansen KW, Christensen CK, Andersen PH, Mau Pedersen M, Christiansen JS, Mogensen CE (1992) Ambulatory blood pressure in microalbuminuric type 1 diabetic patients. Kidney Int 41:847-854
54. Thomas W, Shen Y, Molitch ME, Steffes MW (2001) Rise in albuminuria and blood pressure in patients who progressed to diabetic nephropathy in the Diabetes Control and Complications Trial. J Am Soc Nephrol 12:333-340
55. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P (2001) The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878
56. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH (1999) Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 319:24-25
57. Hansen HP, Lund SS, Rossing P et al (2001) Preventing diabetic nephropathy: an audit. Scand J Clin Lab Invest 61:471-477
58. Almdal T, Nørgaard K, Feldt-Rasmussen B, Deckert T (1994) The predictive value of microalbuminuria in IDDM. Diabetes Care 17:120-125
59. The Diabetes Control and Complications Trial Research Group (1995) Effect of intensive therapy on the development and progression of diabetic nephropatliy in the diabetes control and complications trial. Kidney Int 47:1703-1720
60. Fioretto P, Steffes MW, Sutherland DER, Goetz FC, Mauer SM (1998) Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69-75
61. Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti GC (1993) Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 342:883-887
62. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE (2002) Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 62:963-970
63. Earle K, Walker J, Hill C, Viberti GC (1992) Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N Engl J Med 326:673-677
64. Tarnow L, Rossing P, Nielsen FS, Fagerudd JA, Poirier O, Parving HH (2000) Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 23:30-33
65. Stuveling EM, Bakker SJ, Hillege HL, de Jong PE, Gans RO, de ZD (2005) Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol Dial Transplant 20:497-508
66. Schalkwijk CG, Poland DC, van DW et al (1999) Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351-357
67. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD (2005) Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia 48:370-378
68. Stehouwer CDA, Stroes ESG, Hackeng WHL, Mulder PGH, den Ottolander GJH (1991) von Willebrand factor and development of diabetic nephropathy in IDDM. Diabetes 40:971-976
69. Hovind P, Hansen TK, Tarnow L et al (2005) Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes 54:1523-1527
70. Hovind P, Tamow L, Oestergaard PB, Parving HH (2000) Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int Suppl 75:S56-S61
71. Steinke JM, Sinaiko AR, Kramer MS, Suissa S, Chavers BM, Mauer M (2005) The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 54:2164-2171
72. Eikmans M, Baelde HJ, Hagen EC, et al (2003) Renal mRNA levels as prognostic tools in kidney diseases. J Am Soc Nephrol 14:899-907
73. Mogensen CE (1976) Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand J Clin Lab Invest 36:383-388
74. Parving HH, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR (1981) A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia 20:457-461
75. Viberti GC, Bilous RW, Mackintosh D, Keen H (1983) Monitoring glomerular function in diabetic nephropathy. Am J Med 74:256-264
76. Rossing P, Hommel E, Smidt UM, Parving HH (1993) Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42:715-719
77. Björck S, Mulec H, Johnsen SA, Nordén G, Aurell M (1992) Renal protective effect of enalapril in diabetic nephropathy. Br Med J 304:339-343
78. Lewis E, Hunsicker L, Bain R, Rhode R (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462
79. Elving LD, Wetzels JFM, van Lier HJJ, de Nobel E, Berden JHM (1994) Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia 37:604-609
80. Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH (2000) Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 23:1725-1730
81. Parving HH (1998) Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 41:745-759
82. Rossing P (1998) Promotion, prediction, and prevention of progression in diabetic nephropathy. Diabetic Med 15:900-919
83. Jacobsen PK (2005) Preventing end stage renal disease in diabetic patients - genetic aspect (part I). J Renin Angiotensin Aldosterone Syst 6:1-14
84. Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving HH (2003) Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol 14:2843-2850
85. Parving HH, Jacobsen P, Tarnow L et al (1996) Deleterious effect of a deletion polymorphism in angiotensin-converting enzyme (ACE) gene on progression of diabetic nephropathy during ACE inhibition. Br Med J 313:591-594
86. Andersen S, Tarnow L, Cambien F et al (2003) Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care 26:1501-1506
87. Kurland L, Melhus H, Karlsson J et al (2001) Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 19:1783-1787
88. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH (2001) Progression of diabetic nephropathy. Kidney Int 59:702-709
89. Rossing P, Hommel E, Smidt UM, Parving HH (1994) Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37:511-516
90. Breyer JA, Bain R, Evans JK et al (1996) Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 50:1651-1658
91. Rossing K, Mischak H, Parving HH et al (2005) Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int 68:193-205
92. Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH (2002) Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 17:1413-1418
93. Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH (2003) Optimal dose of Candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized crossover study. Diabetes Care 26:150-155
94. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH (2005) Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 68:1190-1198
95. Hollenberg NK, Fisher NDL, Price DA (1998) Pathways for angiotensin II generation in intact human tissue. Evidence from comparative pharmacological interruption of the renin system. Hypertension 32:387-392
96. Cao Z, Bonnet F, Candido R et al (2002) Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 13:1773-1787
97. Mogensen CE, Neldam S, Tikkanen I et al (2000) Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321:1440-1444
98. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH (2002) Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 17:1019-1024
99. Rossing K, Christensen PK, Jensen BR, Parving HH (2002) Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 25:95-100
100. Andersen NH, Poulsen PL, Knudsen ST et al (2005) Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 28:273-277
101. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH (2003) Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 63:1874-1880
102. Nakao N, Yoshimura A, Morita H et al (2003) Combination therapy of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease: a randomized, controlled trial in Japan (COOPERATE). Lancet 361:117-124
103. Epstein M (2001) Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 19:829-842
104. Sato A, Hayashi K, Naruse M, Saruta T (2003) Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41:64-68
105. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH (2004) Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47:1936-1939
106. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH (2005) Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28:2106-2112
107. Schjoedt KJ, Rossing K, Juul T, Boomsma F, Tarnow L, Parving HH (2005) Beneficial impact of spironolactone in diabetic nephropathy. Diabetologia 48:A6 (Abstract)
108. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH (1996) Predictors of mortality in insulin dependent diabetes: 10 year follow-up study. BMJ 313:779-784
109. Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 310:356-360
110. MacLeod JM, Lutale J, Marshall SM (1995) Albumin excretion and vascular deaths in NIDDM. Diabetologia 38:610-616
111. Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH (1995) Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44:1303-1309
112. Knowles HCJ (1971) Long-term juvenile diabetes treated with unmeasured diet. Trans Assoc Am Physicians 84:95-101
113. Parving HH, Jacobsen P, Rossing K, Smidt UM, Hommel E, Rossing P (1996) Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 49:1778-1782
114. Astrup AS, Tarnow L, Rossing P, Pietraszek L, Riis HP, Parving HH (2005) Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study. Kidney Int 68:1250-1257
115. Brenner BM, Garcia DL, Anderson S (1988) Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens 1:335-347